TOMM20 Antibody (1074702) [Alexa Fluor™ Plus 680]

• Reactivity: Hu
• Clone: 1074702
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 680

TOMM20 Antibody (1074702) [Alexa Fluor™ Plus 680] Summary

• Specificity: Detects a synthetic peptide specific for human TOMM20 containing amino acid 55 in Direct ELISA.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TOMM20 Antibody (1074702) [Alexa Fluor™ Plus 680]

• KIAA0016Outer mitochondrial membrane receptor Tom20
• MAS20
• MGC117367
• mitochondrial 20 kDa outer membrane protein
• mitochondrial import receptor subunit TOM20 homolo
• mitochondrial import receptor subunit TOM20 homolog
• MOM19
• outer mitochondrial membrane receptor Tom20
• TOM20
• TOMM20
• translocase of outer mitochondrial membrane 20 hom
• translocase of outer mitochondrial membrane 20 homolog (yeast)
• translocase of outer mitochondrial membrane 20 homolog type II

Background

TOMM20 (Translocase of Outer Mitochondrial Membrane 20) is a receptor and key unit of the TOM complex.  The TOM complex translocates proteins produced from nuclear DNA through the mitochondrial membrane for use in oxidative phosphorylation.  TOMM20 is a conserved outer membrane protein and depletion of TOMM20 produces a large number of dysfunctional mitochondria with the loss of membrane potential.  Increased TOMM20 expression has been associated with malignancy of various cancers and contributes to tumorigenesis.

1. Park SH, Lee AR, Choi K, Joung S, Yoon JB, Kim S. TOMM20 as a potential therapeutic target of colorectal cancer. BMB Rep. 2019 Dec;52(12):712-717. doi: 10.5483/BMBRep.2019.52.12.249. PMID: 31818360; PMCID: PMC6941759.Nijenjuis M., Hämmerling GJ.  J Immunol. 1996 Dec 15;157(12):5467-77.
2. Yin L, Ye Y, Zou L, Lin J, Dai Y, Fu Y, Liu Y, Peng Y, Gao Y, Fu Y, Qi X, Deng T, Zhang S, Li X. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer. J Exp Clin Cancer Res. 2023 Aug 10;42(1):204. doi: 10.1186/s13046-023-02776-0. PMID: 37563661; PMCID: PMC10413764.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.